Myths vs facts: CYP1A2 and gut health

CYP1A2 is a cytochrome P450 enzyme primarily known for metabolizing caffeine and other xenobiotics. A common myth is that your CYP1A2 genotype directly determines gut health. In reality, the evidence for a direct link is weak. While CYP1A2 is expressed in the gut and can influence the metabolism of dietary compounds, gut health is overwhelmingly driven by the microbiome, fiber intake, inflammation, and lifestyle. Some studies suggest that slow metabolizers (e.g., carriers of the rs762551 A allele) process caffeine more slowly, but this has no proven clinical impact on gut barrier function or microbial diversity. Consumer DNA tests often overstate the role of single genes. MyBody-X offers CYP1A2 analysis, but results should not be used to make gut health decisions. The evidence is mostly mechanistic and lacks robust human studies. Thus, the myth is debunked; the facts are based on limited, indirect evidence.